Famitinib
Phase 3Small molecule
Famitinib is a small molecule that works as a Platelet-Derived Growth Factor Receptor Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase Receptor FLT3 Inhibitor; Vascular Endothelial Growth Factor Receptor 1 Inhibitor; Vascular Endothelial Growth Factor Receptor 2 Inhibitor; Vascular Endothelial Growth Factor Receptor 3 Inhibitor.[2] It is being investigated across 7 indications, with its most advanced program in Phase 3.[1]
Famitinib is one of 209 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Phase 3.
7
Indications
40
Total Trials
11
Active Trials
208
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Famitinib
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Lexiscan
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Duragesic
CCephalon
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tianeptine
PfizerPreclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer7 trials
Show 4 more trials
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04733417·35 enrolled
Nasopharyngeal Carcinoma3 trials
Intrahepatic Cholangiocarcinoma2 trials
Non-Small Cell Lung Cancer2 trials
24 more indications
Adjuvant Treatment1 trial
Metastatic Renal Cell Cancer1 trial
Chemotherapy1 trial
Camrelizumab1 trial
Gynecological Tumors1 trial
Colorectal Adenocarcinoma1 trial
Patients With Advanced Solid Tumors1 trial
Advanced Solid Tumor1 trial
Pancreatic Neuroendocrine Tumor1 trial
Gastrointestinal Stromal Tumour1 trial
Interaction1 trial
First-line Treatment1 trial
Gastrointestinal Stromal Tumor1 trial
Advanced NSCLC1 trial
Osteosarcoma1 trial
Cervical Cancer1 trial
Ovarian Cancer1 trial
Pancreatic Cancer1 trial
A Prospective, Exploratory Study of Retlirafusp Alfa Combined With Famitinib and AG-Chemotherapy as First-Line Therapy for Unresectable Pancreatic Cancer
Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT07814859·88 enrolled
Advanced Breast Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Famitinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Platelet-Derived Growth Factor Receptor Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase Receptor FLT3 Inhibitor; Vascular Endothelial Growth Factor Receptor 1 Inhibitor; Vascular Endothelial Growth Factor Receptor 2 Inhibitor; Vascular Endothelial Growth Factor Receptor 3 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]